Unknown OBSERVATIONAL NCT00418743

Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC)

A Phase II Randomised Trial of Second-line Treatment in Patients With Small Cell Lung Cancer (SCLC), Comparing Oral Combination Chemotherapy (CCNU, Cyclophosphamide, Etoposide) With Intravenous Association Chemotherapy.

Sponsor: Amgen

Conditions Small Cell Lung Cancer

Updated 7 times since 2017 Last updated: Mar 8, 2010 Started: Dec 31, 2005 Completion: May 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This observational or N/A phase trial investigates Small Cell Lung Cancer and is currently ongoing. Amgen leads this study, which shows 7 recorded versions since 2005 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Unknown
Sep 2024 — Sep 2025 [monthly]

Unknown
Jul 2024 — Sep 2024 [monthly]

Unknown

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status
Jun 2018 — Jan 2021 [monthly]

Unknown Status

▶ Show 2 earlier versions

Apr 2018 — Jun 2018 [monthly]

Unknown Status

Phase: PHASE2 → None
Jan 2017 — Apr 2018 [monthly]

Unknown Status PHASE2

First recorded

Dec 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen
Baxter Healthcare Corporation
Groupe Francais De Pneumo-Cancerologie

Data source: Groupe Francais De Pneumo-Cancerologie

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Angers, France , Bastia, France , Beauvais, France , Brest, France , Caen, France , Cergy-Pontoise, France , Créteil, France , Draguignan, France , Elbeuf, France , Gap, France and 13 more locations